Want to see RXST full AI Analyst Report?
RXST Stock Chart & Stats
$6.40
$0.28(5.49%)
At close: 4:00 PM EDT
$6.40
$0.28(5.49%)
Day’s Range― - ―
52-Week Range$4.40 - $13.22
Previous CloseN/A
Volume112.75K
Average Volume (3M)758.51K
Market Cap
$195.07M
Enterprise Value$1.77M
Total Cash (Recent Filing)$208.80M
Total Debt (Recent Filing)$10.58M
Price to Earnings (P/E)―
Beta1.25
Next Earnings
Nov 03, 2026EPS Estimate
-0.31Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.13
Shares Outstanding41,593,258
10 Day Avg. Volume741,787
30 Day Avg. Volume758,506
Financial Highlights & Ratios
PEG Ratio-0.32
Price to Book (P/B)1.56
Price to Sales (P/S)3.19
P/FCF Ratio-22.18
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue0.01
Enterprise Value/Gross Profit0.02
Enterprise Value/Ebitda-0.04
Forecast
1Y Price Target
$7.57Price Target Upside18.26% Upside
Rating ConsensusHold
Number of Analyst Covering10
EPS Forecast (FY)-0.94
Revenue Forecast (FY)$147.04M
Bulls Say, Bears Say
Bulls Say
Scaled Revenue And Gross MarginThe company has demonstrated meaningful commercialization progress while substantially improving product economics. Revenue scale and a gross margin near 77% provide a foundation for operating leverage, reinvestment, and stronger future earnings potential if demand growth resumes.
Liquidity And Financial FlexibilitySubstantial liquidity gives RxSight resources to fund sales expansion, product development, and operational improvements without immediate reliance on external financing. This financial cushion is particularly valuable while the company works to increase utilization and move toward self-funded operations.
Clinical Platform ValidationBroad clinical evidence and physician confidence can support adoption of the Light Adjustable Lens platform and strengthen its differentiation in cataract care. Durable clinical validation may help convert surgeons, improve patient acceptance, and support recurring lens demand as the installed base expands.
Bears Say
Persistent Cash Burn And LossesRxSight remains dependent on its liquidity while operations are not yet self-funding. Persistent losses and negative cash generation can constrain investment flexibility over time, increase the importance of successful growth execution, and create financing or dilution risk if profitability does not improve.
Declining Core DemandThe decline in core product sales indicates that adoption and procedure activity are currently under pressure, rather than growth simply moderating from a high base. Sustained weakness would slow recurring lens revenue, reduce leverage on the commercial infrastructure, and delay the path to profitability.
Execution And Forecasting UncertaintyWithdrawing guidance signals that management needs greater visibility into demand, competition, utilization, or strategic priorities before committing to targets. This uncertainty makes planning more difficult, raises execution risk over the next several quarters, and suggests the business model is still being refined.
RxSight News
RXST FAQ
What was RxSight’s price range in the past 12 months?
RxSight lowest stock price was $4.40 and its highest was $13.22 in the past 12 months.
What is RxSight’s market cap?
RxSight’s market cap is $195.07M.
When is RxSight’s upcoming earnings report date?
RxSight’s upcoming earnings report date is Nov 03, 2026 which is in 13 days.
How were RxSight’s earnings last quarter?
RxSight released its earnings results on Aug 05, 2026. The company reported -$0.29 earnings per share for the quarter, beating the consensus estimate of -$0.329 by $0.039.
Is RxSight overvalued?
According to Wall Street analysts RxSight’s price is currently Undervalued.
Does RxSight pay dividends?
RxSight does not currently pay dividends.
What is RxSight’s EPS estimate?
RxSight’s EPS estimate is -0.31.
How many shares outstanding does RxSight have?
RxSight has 41,593,258 shares outstanding.
What happened to RxSight’s price movement after its last earnings report?
RxSight reported an EPS of -$0.29 in its last earnings report, beating expectations of -$0.329. Following the earnings report the stock price went down -3.339%.
Which hedge fund is a major shareholder of RxSight?
Currently, no hedge funds are holding shares in RXST
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
RxSight Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$7.57 (18.26% Upside)
$7.57 (18.26% Upside)
Blogger Sentiment
Neutral
RXST Sentiment 100%
Sector Average 67%
Sector Average 67%
Hedge Fund Trend
Decreased
By 123.1K Shares
Last Quarter.
Last Quarter.
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-42.79%
12-Months-Change
Fundamentals
Return on Equity
-17.35%
Trailing 12-Months
Asset Growth
14.14%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
RxSight
As a medical technology enterprise, RxSight, Inc. (which operated as Calhoun Vision, Inc. until its rebranding in February 2017) specializes in the innovation, manufacturing, and distribution of light-adjustable intraocular lenses (LALs). These advanced lenses are specifically designed for use in cataract surgery, serving patients in both domestic and international markets. The cornerstone of the company's offerings is the RxSight system, a sophisticated solution that enables ophthalmologists to precisely tailor and enhance a patient's visual acuity following cataract removal. An integral part of this system is the RxSight light delivery device, an in-office instrument. This device emits UV light in a carefully controlled pattern to modify the LAL, thereby ensuring optimal visual correction after the surgical procedure. RxSight's primary clientele consists of eye surgeons specializing in cataract treatments. The company was founded in 1997 and its corporate headquarters are situated in Aliso Viejo, California.
RXST Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call mixed notable strategic and clinical positives — most prominently the Alcon collaboration, solid clinical evidence, a healthy cash position (plus post-quarter $60M upfront), and new commercial leadership with plans to expand the sales force — alongside material near-term operational and financial challenges: a 19% decline in product sales, a 9% drop in LAL volumes, gross margin pressure from inventory, a reported net loss, and the withdrawal of full‑year guidance while management completes an assessment. Management presented a concrete action plan and resources to address utilization and execution, but near-term execution risk and competitive trialing remain.View all RXST earnings summariesRXST Stock 12 Month Forecast
Average Price Target
$7.57
▲(18.26% Upside)
Technical Analysis
Ownership Overview
6.40% Insiders
15.38% Mutual Funds
0.10% Other Institutional Investors
64.12% Public Companies and
Individual Investors